CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Income Statement [Abstract]
Net revenues	$ 137,547	$ 134,695	$ 535,031
Cost of revenues	27,727	26,385	114,877
Gross profit	109,820	108,310	420,154
Operating costs and expenses:
Research, development and clinical studies	42,234	45,916	201,303
Sales and marketing	37,884	31,357	137,057
General and administrative	30,508	31,125	126,127
Total operating costs and expenses	110,626	108,398	464,487
Operating income (loss)	(806)	(88)	(44,333)
Financial expenses (income), net	1,709	2,646	7,742
Income (loss) before income tax	(2,515)	(2,734)	(52,075)
Income tax	2,132	1,394	6,276
Net income (loss)	$ (4,647)	$ (4,128)	$ (58,351)
Basic net income (loss) per ordinary share (in usd per share)	$ (0.04)	$ (0.04)	$ (0.56)
Weighted average number of ordinary shares used in computing basic net income (loss) per share (in shares)	104,186,120	102,633,545	103,433,274
Diluted net income (loss) per ordinary share (in usd per share)	$ (0.04)	$ (0.04)	$ (0.56)
Weighted average number of ordinary shares used in computing diluted net income (loss) per share (in shares)	104,186,120	102,633,545	103,433,274